UNSPSC 41151627: Mass spectrometer for clinical use

In this classification a mass spectrometer for clinical use is a device intended to identify inorganic or organic compounds (e.g., lead, mercury, and drugs) in human specimens by ionizing the compound under investigation and separating the resulting ions by means of an electrical and magnetic field according to their mass US FDA regulates Mass spectrometer for clinical use under 21 CFR 862.2860 and under FDA product code DOP.

UNSPSC 41151627 Mass spectrometer for clinical use (Commodity) shows minimal recent activity aligned with the code's nominal scope. The single opportunity matching the code's title—Harris County, Texas requesting an RFP for a unit dose packaging system posted September 4, 2026 with proposals due October 19, 2026—lacks substantive detail and does not clearly describe clinical mass spectrometry procurement. The remaining opportunities in the dataset, predominantly from Mississippi State University and other academic institutions, cover laboratory analytical instruments (Dynamic Mechanical Analyzers, X-ray diffractometers, nanoindentation systems, cold spray additive manufacturing platforms, acoustic telemetry receivers, and spectrometer systems) that fall outside clinical mass spectrometry practice. These academic research procurements, while equipment-intensive and high-value, target materials characterization, aerospace engineering, environmental monitoring, and basic research rather than clinical diagnostics or therapeutic drug monitoring—the domains where clinical mass spectrometers operate.

The code exhibits no discernible pattern of state and local government procurement for clinical-grade mass spectrometry systems. The Harris County opportunity provides insufficient detail to assess whether a clinical spectrometer is actually being sought. State universities account for the bulk of analytical instrumentation activity in the dataset, but their purchases target research and engineering applications rather than clinical laboratory operations. Geographic concentration appears limited to Texas and Mississippi among the opportunities presented, with no evidence of multistate clinical laboratory procurement activity. The absence of solicitations from health departments, hospital systems, clinical laboratories, or public health agencies—typical end-users of clinical mass spectrometry—suggests either that this UNSPSC code is rarely applied to actual clinical procurement or that clinical mass spectrometry acquisitions are coded differently in state and local systems. Business development professionals should treat this code as currently quiet for clinical applications and verify coding practices with specific procurement offices before committing resources to pursuit.